STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 41,867	$ 23,028	$ 135,082
Operating expenses:
Cost of goods sold	7,266
Research and development	91,879	82,701	107,851
General and administrative	30,257	29,410	21,846
Total operating expenses	129,402	112,111	129,697
Operating (loss) income	(87,535)	(89,083)	5,385
Other income, net	2,061	642	2,334
(Loss) income before income tax benefit	(85,474)	(88,441)	7,719
Income tax benefit	0	0	691
Net (loss) income	$ (85,474)	$ (88,441)	$ 8,410
Net (loss) income per share:
Basic	$ (1.59)	$ (1.74)	$ 0.18
Diluted	$ (1.59)	$ (1.74)	$ 0.18
Weighted average shares:
Basic	53,653,564	50,718,765	47,413,250
Diluted	53,653,564	50,718,765	47,915,030
Other comprehensive loss, net of tax of $0:
Change in unrealized losses on available-for-sale marketable securities	$ (1,314)	$ (431)	$ (97)
Total comprehensive (loss) income	(86,788)	(88,872)	8,313
Collaborative Revenue
Revenue:
Total revenue	16,572	706
License and Milestone Fees
Revenue:
Total revenue	15,000	21,223	134,439
Commercial Supply Revenue
Revenue:
Total revenue	10,223	701
Clinical Compound Revenue
Revenue:
Total revenue		$ 398	$ 643
Royalty Revenue
Revenue:
Total revenue	$ 72